Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > LACK OF TRUST AND INVESTOR CONFIDENCE

<< Previous

Bullboard Posts

Next >>

Comment by forhandlarenon Sep 26, 2024 12:51am

120 Views

Post# 36241546

RE:RE:LACK OF TRUST AND INVESTOR CONFIDENCE

I'm not defending Howard, but what you suggest is simply not true.

Yes, Howard has stated that the Abbvie deal revenue should make the company profitable.

The management claims they are prohibited to give away any information about Abbvie product launch.

The NR states that the company should be profitable during 2025 due to anti-aging launch.

This does not imply that the Abbvie product won't be launched in 2025. It could be launched and make the company profitable by itself the same year, but they are not aloud to inform the shareholders about the timing.

<< Previous

Bullboard Posts

Next >>

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload